Krajina I, Stefanic M, Drenjancevic I, Milic J, Kolobaric N, Pluzaric V
Nutrients. 2025; 17(4).
PMID: 40005022
PMC: 11858809.
DOI: 10.3390/nu17040693.
Geneva-Popova M, Popova-Belova S, Popova V, Stoilov N
Diagnostics (Basel). 2022; 12(5).
PMID: 35626414
PMC: 9140193.
DOI: 10.3390/diagnostics12051260.
Tripolino C, Ciaffi J, Ruscitti P, Giacomelli R, Meliconi R, Ursini F
Front Med (Lausanne). 2021; 8:737573.
PMID: 34631755
PMC: 8492931.
DOI: 10.3389/fmed.2021.737573.
Zhang Y, Liu L, Sun X, Li H, Wang Y, Zhou M
Front Med (Lausanne). 2021; 8:645550.
PMID: 34268318
PMC: 8275838.
DOI: 10.3389/fmed.2021.645550.
Kirmit A, Kader S, Aksoy M, Bal C, Nural C, Aslan O
Postepy Dermatol Alergol. 2020; 37(3):333-339.
PMID: 32792872
PMC: 7394161.
DOI: 10.5114/ada.2020.94265.
Inflammatory marker alteration in response to systemic therapies in psoriasis.
Grechin C, Gheuca Solovastru L, Vata D, Patrascu A, Ioana Grajdeanu A, Porumb-Andrese E
Exp Ther Med. 2020; 20(1):42-46.
PMID: 32508991
PMC: 7271695.
DOI: 10.3892/etm.2020.8535.
Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?.
Nemeth B, Peter I, Boncz I, Jagicza A, Kiss I, Csergo A
Ther Clin Risk Manag. 2019; 15:831-837.
PMID: 31308681
PMC: 6616299.
DOI: 10.2147/TCRM.S197633.
Evaluation of Serum Adenosine Deaminase and Inflammatory Markers in Psoriatic Patients.
Moustafa Y, Elsaied M, Abd-Elaaty E, Elsayed R
Indian J Dermatol. 2019; 64(3):207-212.
PMID: 31148859
PMC: 6537700.
DOI: 10.4103/ijd.IJD_420_17.
Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients.
Khan S, Agrawal S, Baral N, Lamsal M
Psoriasis (Auckl). 2018; 8:59-63.
PMID: 30234006
PMC: 6130266.
DOI: 10.2147/PTT.S174119.
Urinary Orosomucoid A Potential Marker Of Inflammation In Psoriasis.
Kustan P, Koszegi T, Miseta A, Peter I, Ajtay Z, Kiss I
Int J Med Sci. 2018; 15(11):1113-1117.
PMID: 30123048
PMC: 6097268.
DOI: 10.7150/ijms.25687.
The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report.
Owczarczyk-Saczonek A, Drozdowski M, Maciejewska-Radomska A, Choszcz D, Placek W
Postepy Dermatol Alergol. 2018; 35(1):53-59.
PMID: 29599672
PMC: 5872240.
DOI: 10.5114/ada.2017.71358.
Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in Psoriasis.
Asad F, Khan M, Rizvi F
Pak J Med Sci. 2018; 33(6):1507-1511.
PMID: 29492087
PMC: 5768853.
DOI: 10.12669/pjms.336.14068.
Evaluation of Anti-Cyclic Citrullinated Peptide Autoantibodies and C-Reactive Protein in Common Autoimmune Skin Diseases with and without Arthritis.
Kumari B, Kumar P, Chaudhary R
J Clin Diagn Res. 2017; 11(7):BC06-BC08.
PMID: 28892879
PMC: 5583789.
DOI: 10.7860/JCDR/2017/27234.10176.
Chronic tophaceous gout in patients with psoriasis.
Lobato L, Coutinho J, Frota M, Schettini A, Santos M
An Bras Dermatol. 2017; 92(1):104-106.
PMID: 28225966
PMC: 5312188.
DOI: 10.1590/abd1806-4841.20174895.
C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B.
Farshchian M, Ansar A, Sobhan M, Hoseinpoor V
An Bras Dermatol. 2016; 91(5):580-583.
PMID: 27828628
PMC: 5087213.
DOI: 10.1590/abd1806-4841.20164655.
Association of Serum Uric Acid Levels in Psoriasis: A Systematic Review and Meta-Analysis.
Li X, Miao X, Wang H, Wang Y, Li F, Yang Q
Medicine (Baltimore). 2016; 95(19):e3676.
PMID: 27175702
PMC: 4902544.
DOI: 10.1097/MD.0000000000003676.
Serum levels of hypersensitive-C-reactive protein in moderate and severe acne.
Namazi M, Parhizkar A, Jowkar F
Indian Dermatol Online J. 2015; 6(4):253-7.
PMID: 26225329
PMC: 4513404.
DOI: 10.4103/2229-5178.160256.
Assessment of lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1, interleukin-6, homocysteine, and uric acid levels in patients with psoriasis.
Ataseven A, Kesli R, Kurtipek G, Ozturk P
Dis Markers. 2014; 2014:541709.
PMID: 24803721
PMC: 3996950.
DOI: 10.1155/2014/541709.
Psoriasis, psoriatic arthritis and risk of gout in US men and women.
Merola J, Wu S, Han J, Choi H, Qureshi A
Ann Rheum Dis. 2014; 74(8):1495-500.
PMID: 24651620
PMC: 4224633.
DOI: 10.1136/annrheumdis-2014-205212.